China’s medicines regulator has called for greater implementation of the Vaccine Administration Law, urging drug regulatory departments to put promoting awareness of the law “at the top of their agenda.”
The new law, which will come into effect at the start of December, tightens the rules surrounding the production, research, and distribution of vaccines.
Following in the wake of public health scandals concerning counterfeit medicines, the law includes severe punishments for individuals that are found to falsify data or cover up problems.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze